FY2027 Earnings Estimate for ATNM Issued By HC Wainwright

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) – Equities research analysts at HC Wainwright issued their FY2027 earnings per share (EPS) estimates for Actinium Pharmaceuticals in a note issued to investors on Tuesday, March 25th. HC Wainwright analyst J. Pantginis anticipates that the company will post earnings per share of ($1.13) for the year. HC Wainwright has a “Buy” rating and a $4.00 price target on the stock. The consensus estimate for Actinium Pharmaceuticals’ current full-year earnings is ($1.41) per share. HC Wainwright also issued estimates for Actinium Pharmaceuticals’ FY2028 earnings at ($1.24) EPS.

Actinium Pharmaceuticals Stock Performance

Actinium Pharmaceuticals stock opened at $1.89 on Friday. The stock’s 50 day moving average price is $1.25 and its two-hundred day moving average price is $1.45. The stock has a market capitalization of $58.96 million, a price-to-earnings ratio of -1.36 and a beta of 0.10. Actinium Pharmaceuticals has a 52-week low of $1.03 and a 52-week high of $10.24.

Hedge Funds Weigh In On Actinium Pharmaceuticals

Several institutional investors have recently made changes to their positions in ATNM. Vontobel Holding Ltd. bought a new stake in Actinium Pharmaceuticals in the 4th quarter valued at about $32,000. Barclays PLC increased its holdings in shares of Actinium Pharmaceuticals by 323.0% during the third quarter. Barclays PLC now owns 42,935 shares of the company’s stock valued at $81,000 after acquiring an additional 32,784 shares in the last quarter. Sei Investments Co. acquired a new position in shares of Actinium Pharmaceuticals during the fourth quarter worth approximately $62,000. Wellington Management Group LLP bought a new position in shares of Actinium Pharmaceuticals in the 3rd quarter worth $112,000. Finally, Bank of America Corp DE grew its position in Actinium Pharmaceuticals by 76.6% in the 4th quarter. Bank of America Corp DE now owns 78,767 shares of the company’s stock valued at $99,000 after purchasing an additional 34,176 shares during the period. Institutional investors and hedge funds own 27.50% of the company’s stock.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).